When someone is in pain, they cannot concentrate on anything other than how to alleviate that pain as quickly as possible, and many times, Tylenol just isn’t enough. The pain associated with injury and surgery is unbearable at times, but many people are understandably cautious about getting prescription narcotics from their doctors because of the obvious habit-forming, addictive risks associated with these medications.

Nutra-Pharma Corp. (OTCQB: NPHC) offers a suitable substitute to these potentially dangerous medications with its Nyloxin product – an all-natural product aimed at treating moderate to severe chronic pain. Chronic pain is defined as pain that lasts longer than three months and may be related to certain medical conditions including diabetes, arthritis, migraines, fibromyalgia, cancer, shingles, sciatica, and previous trauma or injury.

Nyloxin is available over the counter and comes in two strengths and three forms, conditional on what is more convenient and applicable to the person in need – an oral spray, a roll-on and a topical gel. This makes choosing your remedy much easier, because some people are wary of the time it takes for pills to work and would rather have a topical application medication to go right to the source of the pain.

Nyloxin is equivalent to 300 doses of aspirin and about 1/30 of a dose of morphine. So, you have a supremely effective method of instant pain relief, literally, in the palm of your hand that has none of the addictive ramifications of morphine. Substituting an all-natural form of pain relief (Nyloxin is derived from cobra venom) for habit forming narcotics or some lower strength over the counter competitors makes more sense for treating pain in an effective, time oriented manner.

Nyloxin is also becoming available all over the world, according to a recent letter to shareholders from Nutra Pharma CEO Rik J. Deitsch. The company announced that it has received acceptance for Nyloxin from CPAM – the medical authority in China – paving the way for distribution in the world’s fastest growing consumer market. Also, Nutra Phama announced its plans to distribute Nyloxin in Canada.

For more information on the company, visit www.NutraPharma.com

Let us hear your thoughts: Nutra Pharma Corp. Message Board

According to recent analysis out late last year from the world’s second largest publisher of premium market reports, MarketsandMarkets, the global market for biomarkers is on-track to grow at a CAGR of 13.58 percent through 2020, reaching upwards of $45.55 billion on the strength of increasing healthcare, as well as R&D spending. A key driver of this growth is the massive importance of biomarkers as an objective means for calculating a pathogenic or pharmacological response to therapeutics, or to gauge the behavior of a normal biological process. Biomarker technology continues to play a pivotal role when it comes to developing cutting-edge diagnostics for ailments such as cancer.

Indeed, the global cancer biomarkers market will continue to be one of the most active segments moving forward according to M&M, and this segment is slated to run at an 11.6 percent CAGR over the same interval. Driven by major players engaged in personalized medicine and molecular diagnostics involving biomarkers, such as global microarray market leader Affymetrix (NASDAQ: AFFX), which was recently reported as having been acquired by competitor Thermo Fisher Scientific (NYSE: TMO) for approximately $1.3 billion, as well as more investor-accessible players, some of whom may have at their disposal technologies that hold the potential to reshape the industry itself.

Such high-profile M&A activity at the heart of the translational research/microarray sector speaks volumes for how hot the space has become, and how much promise it holds for the future of medicine. One of the areas in oncology diagnostics that bears consideration is ovarian cancer, due to the specific challenges and concerns associated with the space. American Cancer Society data indicates that roughly 21,300 women in the U.S. alone were diagnosed with ovarian cancer last year, leading to approximately 14,200 tragic deaths. With an overall five-year survival rate of only 45 percent, ovarian cancer is the fifth most common cause of cancer-related death among women, and the risk is highest in women over the age of 55.

Given the high five-year survivability rate of around 93 percent for ovarian cancer, if it is detected in the early stage in which the symptoms are often ignored – compared to an only 18 percent five-year survivability rate if it is detected in later stages – the benefits of advanced warning and pre-symptomatic screening using a definitive, cost-effective diagnostic test cannot be overstated. This is especially true for patients who are found to have platinum-resistant/refractory ovarian cancer, as such patients have an extremely poor prognosis and may also be classed as having chemotherapy-resistant/refractory ovarian cancer.

The standard approach to ovarian cancer utilizes the combination of a platinum compound such as Bristol-Myers Squibb’s (NYSE: BMY) (OTC: BMYMP) Platinol® (cisplatin) or Paraplatin® (carboplatin), and a Taxane, such as Sanofi’s (NYSE: SNY) Taxotere® (docetaxel), or Phyton Biotech’s Taxol® (paclitaxel). But for patients with platinum-resistant/refractory ovarian cancer, early detection is really the brass ring, even with such good news out recently as Merck (NYSE: MRK) and Pfizer (NYSE: PFE) receiving FDA approval for the first Phase III study of avelumab, an investigational, fully human PD-L1 (programmed death-ligand 1) inhibitor that could emerge as a treatment for platinum-resistant/refractory ovarian cancer.

Suffice it to say, this is a market ripe for a simplified microarray-based blood test for early detection of ovarian cancer, including tests like Avant Diagnostics’ (OTCQB: AVDX) OvaDx®, which possesses numerous advantages over the standard CA 125 protein biomarker test for ovarian cancer. Advantages include a sample size of only a few drops and the elimination of needle blood draws, factors which allow for high-volume screening throughput at even smaller facilities. A simplified test like OvaDx, which uses sample shipping and storage on room temperature blood cards and nevertheless yields definitive diagnostic results that allow for detection of early stage ovarian tumor cell development, is a real triumph for women’s health. OvaDx could be a game changer for the $2 billion plus ovarian cancer diagnostic market and might just put AVDX in the immuno-oncology pole position.

The recent announcement that AVDX has entered into an LOI with regenerative medicine, neurology and orphan disease-focused Amarantus Bioscience Holdings (OTCQX: AMBS) to merge the wholly-owned diagnostics subsidiary of Amarantus into AVDX is further proof of how hot the sector is overall. Amarantus Diagnostics’ MSPrecise®, a neuroimmunology-based sequencing assay for multiple sclerosis, also adds mightily to AVDX’s already promising diagnostics footprint. The $1 billion market potential possible in addressing the woefully inaccurate diagnostics market for multiple sclerosis stands to make the combined company a force to be reckoned with. Adding to this emerging diagnostic juggernaut’s appeal is the $3 billion potential of Amarantus Diagnostics’ LymPro Test® for Alzheimer’s disease, another early detection-focused marvel that could revolutionize treatment options for Alzheimer’s patients.

For more information, visit www.avantdiagnostics.com

Let us hear your thoughts: Avant Diagnostics, Inc. Message Board

Talk is cheap, and action – or results to be more accurate – defines whether a company is going in the right direction. There are many innovative ‘idea companies’ out there, but one company making good on its promises and delivering revenue growth, new partnerships, and new products is Content Checked Holdings, Inc. (OTCQB: CNCK). In a recent letter to its shareholders, Content Checked CEO Kris Finstad recapped a rapid, exciting growth history while outlining plans for moving forward.

Fundamentals are the baseline measurement for any small-cap startup company to gauge whether or not it is going in the right direction. For the six months ended September 30, 2015, Content Checked’s revenues were $657,850, as compared to no revenues for the six months ended September 30, 2014. Cash and equivalents as of September 30, 2015, were $5.5 million. Those figures answer these two questions with an unequivocal yes: 1) Are people actually buying your product?; and 2) Do you have enough money in the bank to execute business operations and strategies moving forward? A positive nod in this regard represents impressive execution and growth for a company founded in July 2013.

Content Checked is the creator of a family of mobile apps for individuals who suffer from food allergies and other dietary needs. As Finstad notes in his shareholder letter, the company has had over 2 million downloads and, more importantly, 66 percent of its users are active at least five times a week.

Leveraging its success, the company is moving to a subscription-based model and has plans to continue to diversify and grow its offerings to include more niche apps within the health and wellness sector.

“We believe that the iOS (Apple) and Android platforms are moving in the direction of subscription-based applications. To capitalize on this trend and stay ahead of our competition, we are making our core apps free, and are also offering users subscription-based versions of our apps that will provide access to additional desired features. With the relaunch and rebrand of Content Checked’s products, anticipated to take place in March 2016, we will introduce a new subscription based service for the Content Checked line of products, in addition to offering an updated and improved experience for core (free) users … The extension of our brand will add value to our family of mobile apps designed for those with dietary restrictions and preferences. We believe that consumers of all ages are continuing to place greater emphasis on healthier food alternatives, and we hope that our family of apps will enable Content Checked to reach every demographic in a household,” explained Finstad.

Another strong point for this emerging player is its ability to establish key industry relationships. In this respect, Content Checked has formed a partnership with Troy Healthcare in which the two companies will use their innovative products, MigraineChecked and Stopain® Migraine, respectively, to help deliver preventative information and fast-acting relief for migraine sufferers.

Content Checked’s products have been given numerous accolades and praise in several high profile media outlets and publications, including Forbes, USA Today, ABC, CBS, NBC, Fox, Los Angeles Business Journal, Yahoo! Travel and Yahoo! Finance, Examiner.com, MSN, PR Newswire, Gourmet Business, Epi-Family.com, The Active Times, Reviewed.com, Business Rockstars, IdeaMensch, Celiac Disease Foundation, Cheapflights.com, Bustle, AllergicLiving, The App Magazine, Great Taste Magazine, Clean Eating, TheDailyMeal.com, DIY Active, Food Allergy & Research Education, SheKnows Media, Smarter Travel and Voices in America and Z Living. The company’s apps will also be featured in upcoming outlets such as Los Angeles Business Journal, Reuters, VentureBeat, MyHeart.net, and Rasmussen Blog.

A look at some of the other spokes in the corporate wheel provides a bit of insight into the company’s business development and proven ability to advance on its growth strategies.

Aside from key management, Content Checked is backed by a team of professionals with the following certifications and/or degrees: registered dietician, certified nutritionist specialist, certified nutrition support clinician, CISSN sports nutrition, masters of nutrition, wellness and health coach and NESDA personal trainer.

Additionally, the company kicked-off 2016 with the formation of a board of advisors to provide guidance to the board of directors and management team. One such advisor is Dr. Marc Siegel, MD FACP, a clinical professor, medical director, author, and medical contributor, reporter, and member of the Fox News Medical A Team, among other notable roles.

Combined, all of these achievements and strategies contribute to Content Checked’s plan to uplist to the NASDAQ or NYSE exchange later this year, an impressive feat that will position the company in front of a broader base of global institutions, funds and retail investors.

“All of us at Content Checked believe that our market capitalization will continue to grow with improving underlying Company fundamentals. We are a young entrepreneurial company that is flexible and continues to adopt to our core markets’ and users’ demands, to ensure that we position the Company to enhance shareholder value going forward,” Finstad concluded in his letter.

For more information, visit www.contentchecked.com

Let us hear your thoughts: ContentChecked Holdings Inc. Message Board

Los Angeles is more than just a constantly sunny city with 75-miles of coastline and some of Southern California’s greatest beaches. It’s also the second largest city in the United States, the most populous city in the state of California and a global tourism destination with a diverse economy in entertainment, culture, media, fashion and so much more. To achieve success in this forward-thinking municipality, entrepreneurs are required to think outside of the box and address unmet needs in their chosen markets. In February 2008, Giggles N’ Hugs, Inc. (OTCQB: GIGL) founder Joey Parsi did just that when he launched the very first Giggles N’ Hugs restaurant in Brentwood, California.

Following its launch, the Giggles N’ Hugs concept proved an immediate success, enjoying both profitability and widespread media coverage. Capitalizing on the viability of its home market, the company’s innovative, family-friendly restaurants caught the attention of some of Los Angeles’s most recognizable parents – including celebrities such as Adele, Drew Barrymore, Mariah Carey and Mark Wahlberg. As a result of this early success, Giggles N’ Hugs was approached by Westfield Corporation (OTC: WEFIF), one of the world’s leading shopping center companies, with an intriguing expansion proposal.

In 2010, Giggles N’ Hugs successfully launched its second restaurant in the Westfield Century City Mall. Because of the company’s attractiveness as a tenant, it was able to secure an agreement stating that the mall was to pay 60 percent of construction costs and make other favorable concessions. Today, Giggles N’ Hugs has expanded its reach to include three locations in the Greater Los Angeles area, and additional growth could be on the horizon.

Last month, the company signed an agreement with Chardan Capital Markets, LLC, a boutique investment bank headquartered in New York, designed to assist Giggles N’ Hugs in finding and connecting with potential investors and business partners. Chardan will also provide invaluable advice and assistance to management preparing to present to financial sources and perform a wide variety of financial advisory services.

Look for the company to continuing promoting financial growth as it takes the necessary steps to prepare for an uplisting to a national exchange later this year. With a proven concept that fills a significant unmet need in the market and addresses the top trends shaping the evolution of the broader restaurant industry, Giggles N’ Hugs is now firmly focused on expanding its reach in markets throughout the country and around the world. Joey Parsi, founder and chief executive officer of Giggles N’ Hugs, echoed this sentiment in a recent news release.

“With the unbelievable management team we now have in place, and having one of the most unique concepts in the restaurant industry… we are ready to explode onto the national scene first with multiple locations in some of the best properties in the country and ultimately around the world.”

Learn more by visiting www.gigglesnhugs.com

Let us hear your thoughts: Giggles ‘N Hugs, Inc. Message Board

It’s pretty hard to hit an increasingly agile moving target like the rapidly-evolving viruses that medical science is forced to contend with these days, especially when medical professionals are handicapped by using drugs that rely on somewhat antiquated approaches and technologies, many of which were initially developed over a century ago. If you think about how quickly a virus strain adapts and evolves, it is no wonder that medical science has a difficult time keeping up.

Even the more sophisticated antiviral technologies in use today often amount to little more than variations on existing approaches. The Vesicular Stomatitis Virus-Ebola Virus vaccine (VSV-EBOV) deployed in frontline clinical trials last year to combat the spread of Ebola throughout West Africa is a prime example. Given that this recombinant, replication-competent vaccine is basically just a genetically engineered virus from the same family as rabies, which has been weaponized to express Ebola glycoproteins and thus provoke an immune response in the host, the threat of the virus mutating around existing (only marginally effective) solutions and escaping containment is a persistent threat which looms large on the horizon.

More importantly, because the lion’s share of existing antiviral agents typically use a method of action that takes place within the cell, such indications are plagued by a host of unwanted side effects that can impair the host’s immune system, as well as healthy cells. Currently in the process of transitioning from a preclinical R&D company to a clinical biotech company sometime within the next 15 months, NanoViricides, Inc. (NYSE MKT: NNVC) may have the answer to this “one step forward, two steps back” problem, which is inherent among rapidly evolving viruses, as well as a comprehensive platform solution for difficult to treat viruses that have gone dangerously underserved.

NanoViricides is a unique biotechnology company focused on nanomedicine and has developed a truly revolutionary, tailorable delivery platform designed to destroy viruses both in and on the body. The company’s wholly novel nanoviricide® class of drug candidates employs a combination of cutting-edge nanotechnology and knowledge of the substantial lack of variance in the receptor site for virus-binding ligands on a virus cell’s surface, even after numerous mutations. This combination of a chemically attached virus-binding ligand (a mimic of the receptor cell surface protein) derived from the virus’s own binding site with a flexible “nanomicelle” polymer allows nanoviricides to seek out and attach to a specific virus particle in bodily fluids and then fully engulf it, using the polymer as a containment vessel. This process, using targeted, stealth ligands designed to fool the virus into thinking the nanoviricide looks biochemically like a superb infection target, ultimately renders the virus cell incapable of infecting other cells and, subsequently, dismantles it with no collateral damage to healthy cells.

As amazing as this method of action may sound when compared to existing vaccine technologies and antivirals, the real beauty of NNVC’s nanoviricide technology is its rapid-prototyping capability. The unique ability of this platform to be used for quickly developing highly optimized, virus-specific drug candidates, which can be tailored for premium pharmacokinetic characteristics, such as sustained effect and diverse routes of administration, is something which grants the company’s nanoviricide technology an enviably disruptive profile. Moreover, the platform also possesses the capacity to be utilized for broad-spectrum indications that can aggress up to 95 percent of known viruses in a cost-effective manner, including historically neglected tropical diseases like Dengue fever and Ebola/Marburg.

With the recent outbreak of the Zika virus across Latin America and the Caribbean (now considered to be pandemic), which has been linked to birth defects such as microcephaly in fetuses born to women who contract the virus, the CDC has issued a travel warning (which was echoed by the agency’s EU equivalent) focused on pregnant women and women who may soon become pregnant. Just this week a mother on Hawaii’s third largest island, Oahu, who was infected with the Zika virus when she was residing in Brazil last year, gave birth to a microcephalic child, echoing the patterns observed in Brazil. An alarming incident rate increase for Zika of over 2,200 percent in Brazil from 2014 to 2015, with over 3,500 cases last year and 46 infant casualties, has prompted growing concern from health officials worldwide, and with the Florida Department of Health reporting that, as of January 19, two cases of Zika have been identified in Miami-Dade, the three- to five-year window currently proposed by Brazilian authorities for the development of a vaccine (in record time) paints an astoundingly clear picture of the inherent potential value of NNVC’s highly-adaptable platform technology.

Transmitted by the same species of mosquito that carries Dengue fever (as well as now being thought to be sexually transmissible), Zika virus, whose symptoms are relatively mild, was initially not considered to be a major threat, even as the number of cases quickly shot up in Brazil. However, an increasingly apparent correlation with birth defects like microcephaly and possibly even the paralytic central nervous system malady, Guillain–Barré syndrome, has turned a lot of heads in the medical community, especially considering the lifelong impairment for children born with such birth defects.

NanoViricides’ development pipeline currently boasts a number of promising primary candidates, from an injectable, as well as orally-administered Influenza candidate (FluCide) aimed at the $33 billion plus vaccine market, to indications for HIV/AIDS, and Herpes. FluCide is quite interesting given the CDC’s own recent acknowledgment that the 2014 to 2015 flu vaccine set record efficacy lows, with a paltry 23 percent reduction to risk of getting the flu. The recent presentation by the CEO of NNVC, Eugene Seymour MD, MPH at Biotech Showcase 2016, illustrated how the company is currently moving full speed ahead with human trials for its lead virucidal herpes (of the eye/cornea) keratitis (inflammation of the cornea) treatment, HerpeCide™. Human clinical trials are currently on-track to begin late this year or in early 2017, and commercially-available HerpeCide would be a most welcome addition to the healthcare system’s existing biomedical arsenal, as ocular herpetic disease in general is a serious challenge for both optometrists and patients.

Herpes keratitis is the leading cause of infectious blindness in the Western world and ultimately requires a corneal transplant when it has progressed to the stage of blindness. Corneal transplant is a difficult procedure that can often fail and the procedure can cost as much as $24,400 on average, according to actuarial intelligence giant Milliman. The major herpes viruses that cause ocular disease (simplex and zoster) quite often bring about immunologic reactions in the host that outlive any active infection as well, meaning that the latent demand for a real solution is considerably larger than the baseline market metrics would indicate.

There are a variety of topical (as well as oral) treatments available, such as GlaxoSmithKline’s (NYSE: GSK) Viroptic (trifluridine), which carries significant toxicity risk, or Pfizer’s (NYSE: PFE) Vira-A (vidarabine), although it has been largely displaced by Aciclovir, due to the former indication’s administration via IV being cumbersome. Oral Aciclovir is available under many different generic brand names, such as GSK’s Zovirax and Eli Lilly’s (NYSE: LLY) Lovir, but side effects like dizziness, nausea, and vomiting, as well as more severe problems such as neurotoxicity in dialysis patients, has continued to daunt this segment of the broader $2 billion plus annual market for herpes simplex virus treatments.

NanoViricides recently completed a transition to its new c-GMP-capable, state-of-the-art production and testing facilities in Connecticut, and has thus graduated into a select handful of small biopharma developers with its own in-house, clinical-quality drug manufacturing footprint. With the capacity to see candidates from design through to scaling up of production for IND submissions and human clinical trials, NNVC now also has the muscle to handle commercial-scale manufacturing when (and if) its candidates are eventually licensed. This logistical capacity, combined with the company’s smart weapon nanoviricide platform, means that NNVC’s most advanced candidates, like HerpeCide and FluCide, stand an excellent chance of seeing eventual commercialization.

This is great news considering that NNVC’s anti-Herpes candidate has shown such great progress in HSV-1 animal model studies thus far, with an over 85 percent survival rate (compared to zero for untreated animals), as well as a marked ability to reduce virus production in cell cultures. Shown to be superior to topical treatment with an Aciclovir formulation, the company’s HerpeCide candidates could emerge as not only a leading treatment in the space, but a real solution for patients dealing with the disease and potentially facing blindness.

For more information, visit www.nanoviricides.com

In a recent news release, GTX Corp. (OTC: GTXO) announced its hiring of Maxim Group LLC, a leading full-service investment banking, securities and wealth management firm, to provide strategic advisory services for the company’s corporate initiatives in 2016. GTXO’s primary goals for the coming months include expanding its global distribution network in Latin America and Asia, ramping up retail channel partners in the U.S., enhancing insurance and subsidized reimbursements, making additional inroads into the autistic community, expanding its IP portfolio, launching innovative new tracking products, exploring cutting-edge robotic technologies and further deploying all three of its current product categories in an effort to grow its subscriber base.

“2015 was a transformative year, we launched three products and added distributors and end users across the globe,” Patrick Bertagna, chief executive officer of GTX Corp., stated in the news release. “After extensive meetings with the Maxim team discussing corporate initiatives for 2016, we felt the timing was right to retain the firm and advance with the roadmap now in place.”

In recent months, GTXO has leveraged the marketability of its flagship product, GPS SmartSole, to garner considerable media and industry attention. In September, the company was featured alongside tech giants Microsoft (NASDAQ: MSFT) and Samsung (OTC: SSNLF) when it claimed second place in the Wearables, Health, Fitness and Wellness category at the 2015 CTIA ‘Hot for the Holidays’ Super Mobility Awards in Las Vegas, Nevada. Two months later, GTXO’s GPS SmartSole was featured in a special report by AARP focusing on gadgets that can make life easier for caregivers.

Currently, more than 100 million people require oversight due to various forms of memory impairment resulting from Alzheimer’s, dementia, autism and traumatic brain injury. GTXO’s GPS SmartSole is specially designed to improve the lives of these individuals by offering discreet, convenient tracking services that give caregivers additional peace of mind. According to the 2013 World Alzheimer’s Report, approximately 60 percent of individuals living with Alzheimer’s will become lost at least once, and 70 percent of those people will become lost three or more times. In these cases, the GPS SmartSole can be a literal lifesaver.

With a growing presence in the burgeoning wearables market (which is set to hit $4.5 billion by 2020), GTXO is in a favorable position to promote sustainable growth in 2016. Look for the company to build on its strong performance and promote maximized shareholder value in the months to come by leveraging its marketable IP portfolio and the considerable financial expertise presented by its newly-announced partnership with Maxim Group.

For more information, visit www.gtxcorp.com

Let us hear your thoughts: GTX Corp. Message Board

Nutra Pharma Corp. (OTCQB: NPHC) hasn’t forgotten about the sufferers of myasthenia gravis (MG). The Coral Springs, Florida-based company announced in December 2015 that it had applied for Orphan Status from the Food and Drug Administration (FDA) for its RPI-78M treatment for MG. RPI-78M, described as modified a-cobra toxin in the FDA Orphan Drug database, has already been granted Orphan Status for the treatment of pediatric multiple sclerosis for sufferers up to the age of 16.

Under the Orphan Drug Act of 1983, a drug to treat a ‘rare disease or condition’ can be granted special status referred to as Orphan Designation or, alternatively, Orphan Status. A ‘rare disease or condition’ is one that, generally, affects ‘less than 200,000 persons in the United States’ or ‘affects more than 200,000 in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for such disease or condition will be recovered from sales in the United States… within 7 years’. In addition, Orphan Status gives access to incentives that include 7-year marketing exclusivity, tax credits (up to 50% of clinical development costs), an exemption/waiver of application fees and general assistance from the Office of Orphan Products Development (OOPD), an agency of the FDA. Although Orphan Status for a drug is not a requirement, developers of Orphan Status drugs may also be awarded grants under the Orphan Products Grants Program.

According to the U.S. National Library of Medicine’s PubMed Health portal, ‘Myasthenia gravis is a rare autoimmune condition in which antibodies produced by the immune system attack the connection between nerves and muscles (the neuromuscular junction). Nerve impulses become blocked, causing muscles to become weak and easily tired. Symptoms fluctuate in severity. Acetylcholine is a chemical messenger that carries signals between nerve and muscle. An enzyme called acetyl-cholinesterase breaks down acetylcholine. Some drugs that are used to treat myasthenia gravis act on acetyl-cholinesterase to stop the breakdown of acetylcholine. These acetyl-cholinesterase inhibitors increase the amount of acetylcholine available and so help muscle activation and contraction.’ Consequently, cholinesterase inhibitors enhance communication between muscles and nerves and may improve muscle contraction and muscle strength.

With RPI-78M, Nutra Pharma is taking a different approach. RPI-78M contains anti-cholinergic peptides that recognize the same receptors as nicotine (acetylcholine receptors) but have the opposite effect. In other words, an anti-cholinergic drug like RPI-78M has the opposite pharmacological action to a cholinesterase inhibitor. An anti-cholinergic works by blocking the action of the neurotransmitter acetylcholine in the brain and so stops involuntary movements of the muscles associated with these diseases.

Nutra Pharma is a biopharmaceutical company engaged in the acquisition, licensing and marketing of homeopathic treatments and ethical drugs for the management of pain, neurological disorders, cancer, auto-immune and infectious diseases. The company, through its subsidiaries, carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma’s subsidiary, ReceptoPharm, is developing technologies for the production of drugs for HIV and Multiple Sclerosis (MS). Another subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma’s clinical drug development costs are partially offset by the revenue from its Nyloxin OTC line of products.

For more information on the company, visit www.NutraPharma.com

Let us hear your thoughts: Nutra Pharma Corp. Message Board

GTX Corporation’s (OTC: GTXO) GPS SmartSole was the focus of a recent article highlighting the latest innovations in wearable tracking devices. The piece, titled “GPS SmartSole Gives Peace of Mind to Parents of Wanderers,” introduces readers to the considerable benefits of the GPS SmartSole, an invisible wearable technology device intended for non-invasive tracking of individuals with cognitive disorders. In the article, Patrick Bertanga, chief executive officer of GTXO, discusses the inspiration for GPS SmartSole, as well as the next steps in the company’s ongoing development of this groundbreaking solution to the unique needs of the roughly nine million people in the U.S. with cognitive memory disorders that cause them to wander.

The article was featured on the blog of Friendship Circle, a social services organization focused on offering support to children with special needs and their families. Friendship Circle is a non-profit organization that provides assistance and support to 3,000 individuals with special needs and their families by offering recreational, social, educational and vocational programs, enriched by the selfless giving of a vast network of volunteers.

To view the full article, visit http://www.friendshipcircle.org/blog/2016/01/19/gps-smartsole-gives-peace-of-mind-to-parents-of-wanderers/

For more information, visit www.gtxcorp.com

Let us hear your thoughts: GTX Corp. Message Board

Everybody loves popcorn, especially as a quick snack before dinner or during a night at the movies. What many people don’t know, however, is that pre-packaged popcorn from the grocery store may contain loads of salt, butter and other artificial flavoring that are terrible for your health. As an alternative to munching these additives, in a recent article published on ZLiving.com, Victoria Brodsky, head of nutrition at Content Checked Holdings, Inc. (OTCQB: CNCK), gives some great tips and recipes for making your own popcorn at home.

Read the full article here: http://www.zliving.com.

As the article notes, popcorn is healthiest when prepared ‘air popped,’ which you can purchase or whip up on your own.

“You can buy air-popped popcorn at your local grocer, or you can make your own by buying kernels and popping them in a paper bag in the microwave,” Brodsky explains in the article.

Another option is to put a third of a cup of popcorn kernels into a medium-sized paper bag, fold the bag with a small half-inch fold, and then stick it in the microwave for two or three minutes. Once the kernels are done popping, add some healthy fat such as olive oil or coconut oil. As an alternative to artificial flavor or sugar, use spices and fresh herbs to elevate the taste and add nutritional boosts to your popcorn.

The article – available to Z Living’s 26,244 unique monthly visitors – has recipes for whatever your taste buds are craving; whether it’s something sweet, salty, or spicy, popcorn can satisfy your cravings and keep your health in mind at the same time.

Though you certainly can use the ContentChecked app to shop for grocery store popcorn, you can also use the app for other foods to know exactly what you’re getting in terms of food allergens and specifics. Brodsky is just one of several professional nutritionists who have helped establish ContentChecked and its family of apps as a reliable source for consumer information and media commentary.

For more information, visit www.contentchecked.com

Let us hear your thoughts: ContentChecked Holdings Inc. Message Board

Earlier today, Moxian, Inc. (OTCQB: MOXC) announced that its subsidiary, Moxian Technologies (Beijing) Co. Ltd., has entered into an exclusive development partnership with Xinhua New Media Culture Communication Co. Ltd. Through this partnership, Moxian will serve as the exclusive seller of advertising space for Xinhua’s popular gaming platform, the Xinhua New Media App. Per the terms of the five-year agreement, Moxian will assist Xinhua with enhancing user retention by offering Mo-Coins and Mo-Points in exchange for interaction with advertisements within the app. After earning these credits, users can log into the Moxian platform in order to redeem their rewards.

“This strategic cooperation agreement with Xinhua New Media Culture Communication Co. Ltd., a Xinhua Media affiliate, lays a solid foundation for Moxian’s future promotions and developments, while also gradually yet effectively driving the Moxian App into the Internet mainstream,” Tan Meng Dong James, chief executive officer of Moxian, stated in the news release.

By partnering with Xinhua, Moxian is expected to gain immediate access to a massive base of active members. According to the news release, the Xinhua New Media App currently boasts more than 110 million registered users, including 10 million daily active users. As the exclusive reseller of advertising space for the app, Moxian is now in a favorable strategic position to dramatically boost its visibility and influence in the market place while quickly expanding upon its existing user base.

Since announcing the formation of its Beijing subsidiary earlier this month, Moxian has wasted no time in establishing a strengthened strategic foothold in the capital of the People’s Republic of China. Moving forward, the company’s subsidiary will continue to focus on growing Moxian sales in Beijing while driving local merchants and users to its social marketing and promotion platform. To date, Moxian Beijing has been staffed with 15 employees, and the company expects to increase its in-house Beijing sales team to 50 salespeople by the end of this year in an effort to maximize market penetration.

The company’s new agreement with Xinhua is a great first step toward maximizing on the market potential presented by its new subsidiary. With a new source of revenue secured, Moxian is in a prime position to capitalize on its boosted visibility and influence in the market space. Look for the company to continue benefiting from its cooperation with Xinhua while garnering a noteworthy boost to its user base in the short term. Tan Meng Dong James echoed this sentiment to conclude today’s news release.

“We look forward to the headway and potential this mutually advantageous deal provides both companies,” he stated.

For more information, visit the company’s website at www.Moxian.com

Let us hear your thoughts: Moxian, Inc. Message Board